Reaction
Nasal Inflammation reporting signals
As of the last recalculation, Nasal Inflammation appears in 1,042 FAERS reports alongside 14 co-occurring drug terms. The strongest observed disproportionality signal is DORNASE ALFA (PRR 31.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Dornase Alfa | 30 | 31.4 | 31.5 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 14 | 22.7 | 22.7 |
| Tobramycin | 23 | 19.5 | 19.5 |
| Fluticasone Furoate | 11 | 18.3 | 18.3 |
| Tobramycin Sulfate | 9 | 14.6 | 14.6 |
| Fluticasone Propionate | 85 | 14.2 | 14.2 |
| Tobramycin Solution | 8 | 13.4 | 13.4 |
| Lumacaftor And Ivacaftor | 5 | 11.7 | 11.7 |
| Desoximetasone | 11 | 11.6 | 11.7 |
| Omalizumab | 45 | 11.0 | 11.0 |
| Mometasone Furoate And Formoterol Fumarate Dihydrate | 8 | 10.3 | 10.3 |
| Fluticasone Furoate And Vilanterol Trifenatate | 17 | 9.6 | 9.6 |
| Lapatinib | 5 | 6.5 | 6.5 |
| Dupilumab | 74 | 3.2 | 3.2 |